Treatment for prolactinomas and hyperprolactinaemia: A lifetime approach

European Journal of Clinical Investigation

Volumn 41, Issue 3, 2011, Pages 334-342

  Mann, W Alexander ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Clinical manifestation; Dopamine agonists; Hyperprolactinaemia; Paediatric hyperprolactinaemia; Postmenopausal hyperprolactinaemia; Prolactinoma

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CABERGOLINE; CIMETIDINE; CLOMIPRAMINE; CYPROTERONE ACETATE; DESIPRAMINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; HALOPERIDOL; HORMONE; IMIPRAMINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; PHENOTHIAZINE; PIMOZIDE; QUINAGOLIDE; RANITIDINE; RESERPINE; RISPERIDONE; UNINDEXED DRUG; VERAPAMIL;

ANXIETY DISORDER; CLINICAL FEATURE; CONSTIPATION; DEPRESSION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FOLLOW UP; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; LIFESPAN; NAUSEA; NOSE CONGESTION; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; PSYCHOSIS; REVIEW; SURGICAL TECHNIQUE; TREATMENT DURATION; VALVULAR HEART DISEASE; VASOSPASM;

DOPAMINE AGONISTS; FEMALE; HEART VALVE DISEASES; HUMANS; HYPERPROLACTINEMIA; MALE; PARKINSON DISEASE; PITUITARY NEOPLASMS; PROLACTINOMA; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79551666733     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02399.x     Document Type: Review

References (70)

1. Molitch ME. Prolactinoma. In: Melmed S, editor. Pituitary. Cambridge: Blackwell Science, 1995:433-77.
2. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet 1998;352:1455-61.
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross- sectional study in the province of Liege, Belgium. Clin Endocrinol Metab 2006;91:4769-75.
4. Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary gland and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981;304:156-8.
5. Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol 1994;41:359-64.
6. Fideleff HL, Boquete HR, Sequera A, Suarez M, Sobrado P, Giaccio A. Peripubertal prolactinomas: clinical presentation and longterm outcome with different therapeutic approaches. J Pediatr Endocrinol Metab 2000;13:261-7.
7. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endo Metab 2002;87:457-65.
8. Hentges S, Sarkar DK. Transforming growth factor-beta regulation of estradiol- induced prolactinomas. Front Neuroendocrinol 2001;22:340-63.
9. Schlechte JA. Clinical practice. Prolactinoma. N Eng J Med 2003;349:2035-41.
10. Snyder PJ, Jacobs LS, Utiger RD, Daughaday WH. Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone. J Clin Invest 1973;52:2324-9.
11. Fideleff HL, Boquete HR, Suarez MG, Azaretzky M. Prolactinoma in children and adolescents. Horm Res 2009;72:197-205.
12. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003;148:325-31.
13. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 2000;85:3053-7.
14. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psych 2004;65:1607-18.
15. Klibanski A, Biller BM, Rosenthal DI, Schonefeld DA, Saxe V. Effects of prolactin and estrogen deficiency in amenorrhoeic bone loss. J Clin Endocrinol Metab 1988;67:124-30.
16. Molitch ME. Medication induced hyperprolactinemia. Mayo Clin Proc 2005;80:1050-7.
17. Di Sarno A, Rota F, Auriemma R, De Martino MC, Lombardi G, Colao A. An evaluation of patients with hyperprolactinemia: have dynamic testings had their day? J Endocrinol Invest 2003;7(Suppl):39-47.
18. Cavaco B, Leite V, Santos MA, Arranhado E, Sobrinho LG. Some forms of big big prolactine behave as complex of monomeric with an immunoglobulin G in patients with macroprolactinoma or prolactinomas. J Clin Endocrinol Metab 1995;80:2342-6.
19. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. Effects of antiprolactin autoantibodies on serum prolactin measurements. Eur J Endocrinol 1994;130:434-7.
20. Hauache OM, Rocha AJ, Maia AC Jr, Maciel RM, Vieira JG. Screening for macroprolactinemia and pituitary imaging studies. Clin Endocrinol (Oxf) 2002;57:327-31.
21. Petakov MS, Damjanović SS, Nikolić-Durović MM, Dragojlović ZL, Obradović S, Gligorović MS et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 1998;21:184-8.
22. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996;44:305-9.
23. Sawers HA, Robb OJ, Walmsley D, Strachan FM, Shaw J, Bevan JS. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinemia. Clin Endocrinol (Oxf) 1997;46:321-6.
24. Naidich MJ, Russell EJ. Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 1999;28:45-79.
25. Von Werder K, Eversmann T, Fahlbusch R. Development of hyperprolactinemia in patients with adenomas with and without prior operative treatment. Excerpta Med Int Congress series 1982;584:175-88.
26. Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril 1987;48:67-71.
27. March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML et al. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 1981;139:835-44.
28. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD et al. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265-73.
29. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in patients with hyperprolactinemia. Fertil Steril 1993;59:671-3.
30. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J. Long-term follow-up of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 1996;45:299-303.
31. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989;68:412-8.
32. Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinemia. Clin Endocrinol (Oxf) 2001;54:295-300.
33. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698-705.
34. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumour shrinkage. Endocr Rev 1992;13:220-40.
35. Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 1985;315:542-6.
36. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. N Engl J Med 1994;331:904-9.
37. Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998;83:807-13.
38. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 2005;8:43-52.
39. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876-83.
40. Colao A, Lombardi G. Prolactinoma apparently resistant to quinagolide respond to cabergoline therapy. J Clin Endocrinol Metab 1997;82:2756.
41. Colao A. The prolactinoma. Clin Endocrinol Metab 2009;23:575-96.
42. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA et al. Treatment of prolactin-secreting macroadenomas with the once weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338-43.
43. Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S et al. Long-term treatment with cabergoline, a new long- lasting ergoline derivate, in idiopathic or tumourous hyperprolactinemia and outcome of drug-induced pregnancy. J Endocrinol Invest 1997;20:547-51.
44. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinoma. Endocr Rev 2006;27:485-534.
45. Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J (Clin Res Ed). 1984;289:1101-3.
46. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
47. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38.
48. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:29-38.
49. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008;93:3348-56.
50. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M et al. Increased prevalence of triscupid regurgitationin patients with prolactinoma chronically treated with cabergoline. J Clin Endocrinol Metab 2008;93:3377-84.
51. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 2008;31:1119-23.
52. Valassi E, Klibanski A, Biller BM. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010;95:1025-33.
53. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000;85:2247-52.
54. Klibanski A. Prolactinomas. N Engl J Med 2010; 362: 1219-26.
55. Klibanski A. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued. J Clin Endocrinol Metab 2009;94:2247-9.
56. Mori H, Mori S, Saitoh Y, Arita N, Aono T, Uozumi T et al. Effects of bromocriptine on prolactin-secreting pituitary adenomas: mechanisms of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and mophometric analysis. Cancer 1985;56:230-8.
57. Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002;87:3578-82.
58. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003;349:2023-33.
59. Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F et al. Predictors of remission of hyperprolactinemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 2007;67:426-33.
60. Kharlip J, Salvatori R, Yenokan G, Wand GS. Recurrence of hyperprolactinemia following withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 2009;94:2428-36.
61. Dekkers OM, Lagro J, Burman P, Joergensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:43-51.
62. Watt A, Pobereskin L, Vaidya B. Pituitary apoplexy within a macroprolactinoma. Nat Endocrinol Diab Metab 2008;4:635-41.
63. Thomson JA, Gray GE, Teasdale GM. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up. Neurosurgery 2002;50:36-40.
64. Barker FG II, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003;88:4709-19.
65. Gillam MP, Fideleff H, Boquete HR, Molitch ME. Prolactin excess: treatment and toxicity. Pediatr Endocrinol Rev 2004;2:108-14.
66. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83:2777-80.
67. De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptin. Eur J Endocrinol 1998;138:286-93.
68. Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985;312:1364-70.
69. Colao A, Abs R, Barcena DG, Chanson P, Paulus W, Kleinberg DL. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year-observational study. Clin Endocrinol (Oxf) 2008;68:66-71.
70. Crosignani PG, Mattei AM, Severini V, Cavioni V, Maggioni P, Testa G. Long term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obs Gyn Rep Biol 1992;44:175-80.